<DOC>
	<DOCNO>NCT01496040</DOCNO>
	<brief_summary>The purpose study assess safety efficacy active substance rAAV-2/4.hRPE65 patient Leber Congenital Amaurosis Congenital severe early-onset retinal degeneration associate RPE65 mutation .</brief_summary>
	<brief_title>Clinical Gene Therapy Protocol Treatment Retinal Dystrophy Caused Defects RPE65</brief_title>
	<detailed_description />
	<mesh_term>Leber Congenital Amaurosis</mesh_term>
	<mesh_term>Blindness</mesh_term>
	<mesh_term>Retinal Dystrophies</mesh_term>
	<criteria>Mutations code abnormal RPE65 protein Presence characteristic abnormality fundus Dramatic reduction rod ans cone ERG response Low visual acuity &lt; 0.32 inform consent sign Patients chronic condition haematological , cardiac , renal disease Patients , within past 6 month , clinically significant cardiac disease know congestive heart failure , cardiac rhytm conduction abnormalities Patients pulmonaty dysfunction Patients suspect rheumatoid arthritis Patients current systemic infection ... ... ..</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>